Please select the eligibility criteria that correspond to the clinical trial below.
Title: e-Learning & Development of an Evidence-based Psychoeducational Programme for First Episode Psychosis
Brief Summary: Treatment delay in psychosis usually lead to slower recovery, an increase in associated comorbidity and greater deterioration in social and family life of patients. Previous studies indicate that an early intervention with guidelines for increasing adherence to treatment, disease awareness and condition management leads to better progression of the disorder and is therefore related to a better prognosis.

Several studies have found that the rate of relapse is higher in patients with pharmacological treatment alone compared to those also receiving psychoeducation, who tend to improve their adherence to treatment and reduce toxic drugs dosage.

Hypotheses:

* Individual psychoeducation will be effective as complementary therapy to pharmacological treatment in patients with a first psychotic episode, improving disease evolution.
* BDNF levels will increase more in the patients receiving individual therapy compared to those without it.
* Psychoeducation can be performed similarly in all participating centers if the therapists receive the same training and use the same psychoeducation material.
* The use of telemedicine for the follow-up of the patients will help improve the welfare work and therefore the disease evolution.


Options:
A: Inclusion Criteria:

* DSM-IV diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, psychosis not otherwise specified or delusional disorder
* Received EASY service for 2 years following a first-episode psychosis
* Cantonese-speaking Chinese
* Ability to understand the study and to provide written informed consent

Exclusion Criteria:

* Organic brain disorder
* Known history of intellectual disability
* Drug-induced psychosis
B: Inclusion Criteria:

* patients aged 18 - 37 years
* first episode psychosis in schizophrenia spectrum
* treated for 1½ year in the five OPUS teams in the Capital Region and the OPUS teams in Region Midt
* patients who will give signed informed consent to participate in the trial

Exclusion Criteria:

* patients who are not treated in one of the OPUS team in the Capital Region and Region Midt
* patients who don't give signed informed consent to participate in the study
C: Inclusion Criteria:

1. Age 16-45
2. Meets DSM-IV schizophrenia spectrum psychosis or affective psychosis according to the SCID
3. ≤8 weeks of received antipsychotic treatment lifetime at time of referral
4. Willing to be treated in New Haven

Exclusion Criteria:

1. Psychosis believed due to substance use (based on the SCID)
2. Unable or unwilling to give informed consent
3. MR as indicated by receipt of services from Dept of Mental Retardation
D: Inclusion Criteria:

* patients who have suffered a first psychotic episode (diagnosis IV-TR) in the last five years,
* age between 18 and 45 years,
* patients who have given written informed consent to participate.

Exclusion Criteria:

* patients with a comorbid disorder that interferes with their ability to communicate,
* patients who received psychoeducation previous to inclusion in study.

Answer: D